Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chlorproguanil + dapsone + artesunate
- Development stage
- Phase 4
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Chlorproguanil + dapsone + artesunate (CDA) was an experimental fixed-dose artemisinin-based combination therapy (ACT) developed for the treatment of acute uncomplicated *Plasmodium falciparum* malaria. Developed through a public-private partnership involving GSK, the Medicines for Malaria Venture (MMV), and the WHO Special Programme for Research and Training in Tropical Medicine (WHO TDR), CDA was designed to be an affordable and effective treatment for use in Africa. The combination utilized three small molecule drugs with distinct mechanisms: chlorproguanil (a dihydrofolate reductase inhibitor), dapsone (a sulfone that inhibits dihydropteroate synthase), and artesunate (an artemisinin derivative that induces rapid parasite clearance). Despite reaching Phase III clinical trials, the development program was discontinued in 2008 after data revealed that the drug caused unacceptable hematological toxicity, specifically post-treatment hemolytic anemia, in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- Brand names
- Lapdap
- Other names
- Chlorproguanil-dapsone-artesunate
02
Targets
PfATP6 (Plasmodium falciparum ATP6)HemeGST (Glutathione S-transferase alpha 3)DHPS (Dihydropteroate synthase)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on chlorproguanil + dapsone + artesunate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chlorproguanil + dapsone + artesunate.